Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05565183
Other study ID # APHP190631
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2022
Est. completion date November 2025

Study information

Verified date August 2022
Source Assistance Publique - Hôpitaux de Paris
Contact Nicolas BADENCO, MD
Phone +33 1 42 16 29 76
Email nicolas.badenco@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atrial The treatment of atrial fibrillation (AF) includes 2 axes: the prevention of the cardio-embolic risk and rhythm control. The possibilities for this control are antiarrhythmic drugs and, above all, catheter ablation, an interventional cardiology technique which consists in treating the areas responsible for the initiation and perpetuation of AF by applying radiofrequency energy or cryotherapy to the myocardial tissue. Limited research has been done on the combination of different parameters to manage AF, especially during the initial stage of the disease. A translational and multimodal approach could make it possible to better characterize this pathology and thus, help to adjust the therapeutic management for the patients. The combined analysis of regional electrophysiological, morphological, and functional parameters of the left atrium could make it possible to better detect early atrial cardiomyopathy and predict recurrences of atrial fibrillation.


Description:

The electrophysiological substrate for patients with persistent atrial fibrillation is heterogeneous with areas of atrial myocardium of low voltage amplitudes and areas of rapid fragmented signals in arrhythmia. The targets of ablation treatment in these cases are currently poorly defined. Several promising strategies have emerged, such as the isolation of fibrotic areas, low voltage. An integration analysis of regional electrophysiological, morphological, and functional parameters of the left atrium, therefore, open up a new area of research that has not been studied to date and could help to better guide the therapeutic management of patients with AF. The study aims to assess the association between regional and global myocardial strain abnormalities on magnetic resonance imaging (MRI) and the amplitude of the atrial intracardiac electrical potential, in young subjects with symptomatic AF.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date November 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Patient aged 18 to 60 years 2. Established diagnosis of paroxysmal or persistent symptomatic atrial fibrillation (AF) for at least 3 months with indication of catheter ablation 3. AF episode documented by ECG in the last 12 months 4. Structurally healthy heart, with an LVEF> 50%, an interventricular septum <12 mm and an OG volume <40mL / m ² by TTE 5. Having given their informed consent in writing 6. Affiliated with or entitled to a French social security scheme Exclusion Criteria: 1. Mitral valve disease with grade 2 to 4 insufficiency 2. Heart failure (NYHA stage II to IV in sinus rhythm and LVEF < 50%), hypertrophic heart disease or congenital heart disease 3. Contraindication to oral anticoagulation 4. Intracardiac thrombus 5. History of ablation of the left atrium 6. History of heart surgery 7. Contraindication to performing MRI or using the DOTAREM™ contrast medium (pacemaker, defibrillator, prosthesis, old generation heart valves, old generation ferromagnetic vascular surgical clips, treatment type endocranial aneurysms, neurosimulator, cochlear implants, automated injection device such as insulin pump, and more generally any non-removable electronic medical device or equipment, kidney disease with GFR < 30 mL/min, hypersensitivity to gadoteric acid or to excipients) 8. History of myocardial infarction or coronary angioplasty within the last three months 9. Chronic obstructive pulmonary disease 10. Under guardianship or curatorship 11. Women who are pregnant, breastfeeding or of childbearing age in the absence of effective contraception 12. Participation in another interventional research involving a health product

Study Design


Intervention

Diagnostic Test:
MRI (with injection of contrast product)
All patients included in the study will undergo two MRI examinations (with injection of contrast product) before and after the ablation procedure.

Locations

Country Name City State
France Institut de Cardiologie de la Pitié-Salpêtrière Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between the regional and global longitudinal strain peaks (percent (%)) and voltage (millivoltage(mV)) of the left atrium measured by MRI and catheter ablation 1 month
Secondary Localization in the left atrium and area of low amplitude electrogram areas (<0.5 mV, <0.3 mV and <0.1 mV) measured during the ablation procedure 1 month
Secondary Localization in the left atrium and areas of fragmented atrial complexes measured during the ablation procedure 1 months
Secondary Local atrial impedance measured by ablation catheter 1 months
Secondary Contact force measured by ablation catheter 1 month
Secondary Local impedance drop measured during radiofrequency delivery 1 month
Secondary Duration of the ablation for each radiofrequency delivery 1 month
Secondary Localization of the segmental and regional alteration of the myocardium in the left atrium measured during MRI 3 months
Secondary Localization of zones with impaired 4D flow in the left atrium measured during MRI 3 months
Secondary Left atrium volume (milliliter (mL)) measured during MRI 3 months
Secondary Localization of areas of late enhancement in the left atrium 3 months
Secondary Lesion transmurality performed by ablation in each segment of the pulmonary veins 3 months
Secondary Subcutaneous measurement (AGE Reader) which combines aging and accumulation of glycated proteins in the subcutaneous tissue measured during MRI 3 months
Secondary Volumes (milliliter (ml)) of the left atrium: in the basal state and after passive filling measured during echocardiography 1 month
Secondary Analysis of the longitudinal deformation (strain) in speckle tracking in the basal state and after passive measured during echocardiography 1 month
Secondary Absence of atrial fibrillation occurrence 12 months
Secondary Absence of persistent atrial fibrillation occurrence 12 months
Secondary Absence of atrial tachycardia or atrial flutter occurrence after catheter ablation 12 months
Secondary Absence of palpitation occurrence after catheter ablation 12 months
Secondary 6-minute walking test to assess exercise capacity 1 month
Secondary Differences in the volumes (milliliter (ml)) of the left atrium (maximum, minimum, atrial pre-systole) between the segmentation performed manually and the segmentation obtained by learning transfer 3 months
Secondary Distance between areas of low voltages identified by the cartography and areas of late 3D enhancement identified by MRI, measurement based on the volume (milliliter (ml)) resulting from CT-scan and MRI fusion 3 months
See also
  Status Clinical Trial Phase
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Recruiting NCT06014996 - Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation. N/A
Completed NCT03624881 - Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) Phase 4
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Recruiting NCT05905835 - Treatment of PAF With the Synaptic System N/A
Active, not recruiting NCT05534581 - SINGLE SHOT CHAMPION Phase 4
Active, not recruiting NCT05618340 - PFA for Paroxysmal Atrial Fibrillation N/A
Not yet recruiting NCT05024630 - Renal Denervation and pUlmonary Vein isolAtion With cryoabLation on Patients With Atrial Fibrillation and hypErtension N/A
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A
Completed NCT01913522 - Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration N/A
Terminated NCT01925885 - Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF) N/A
Withdrawn NCT01917981 - Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation Phase 3
Completed NCT01693107 - Atrial Fibrillation Force Contact Ablation Study
Completed NCT01842529 - Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery Phase 2
Completed NCT00971204 - Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation Phase 2
Completed NCT05043883 - Automated Assessment of PVI Using a Novel EP Recording System N/A
Recruiting NCT05172765 - Biomarker-Guided Optimization of Transcutaneous Vagal Stimulation for Atrial (BiG tVNS-AF) N/A
Recruiting NCT04529785 - Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation N/A
Completed NCT04022954 - HD Mapping of Atrial Fibrillation in Asia Pacific
Completed NCT00964392 - NAVISTAR® THERMOCOOL® Catheter Post Approval Registry Phase 4